Dupixent(R) (dupilumab) Approved for Severe Asthma by European Commission

Only biologic approved in the EU for severe asthma with type 2 inflammation, as characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO) In clinical trials, Dupixent improved lung function and quality of life, and r... Biopharmaceuticals, Regulatory Regeneron Pharmaceuticals, Sanofi, Dupixent, dupilumab, asthma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news